Safety data is clean but the sentinel cohort is too small for efficacy conclusions. The main cohort readout in 2027 is the key catalyst. Monitor for any early efficacy signals or regulatory interactions in the interim.
Price Chart
Executive Summary
Vaxart reported topline 12-month safety data from the 400-participant sentinel safety cohort of its Phase 2b oral pill COVID-19 vaccine trial. No vaccine-related serious adverse events or sustained Grade 3+ adverse events were observed in either the oral vaccine or mRNA comparator arms. The complete study data, including the ~5,000-participant main cohort, is anticipated in 2027.
Key Facts
- Topline 12-month safety data from ~400-participant sentinel safety cohort of Phase 2b oral pill COVID-19 vaccine trial
- No vaccine-related serious adverse events (SAEs) or sustained Grade 3+ adverse events in either arm
- 201 participants received oral pill vaccine; 199 received approved mRNA vaccine targeting XBB strain
- Most common AEs in oral vaccine arm: malaise/fatigue (20.9%), headache (18.9%), anorexia (10.0%)
- Most common AEs in mRNA arm: injection site pain (60.3%), injection site tenderness (40.2%), malaise/fatigue (35.2%)
- Symptomatic COVID occurred in 33 oral vaccine recipients vs 30 mRNA recipients; cohort not powered for efficacy
- Complete study data (sentinel + ~5,000 main cohort) expected in 2027
- Project NextGen/BARDA award valued at up to $344.8 million
Financial Impact
No financial data reported; BARDA award up to $344.8 million referenced but no current revenue or earnings impact
Risk Factors
- Efficacy may not replicate in the larger main cohort
- Complete study data not expected until 2027, creating a long wait for a pivotal catalyst
- Competition from approved mRNA and other COVID vaccines
- Reliance on BARDA funding which could be modified or terminated
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-022876 |
| Exhibit: ex_985231.htm | 0001437749-26-022876 |
| Document: 0001437749-26-022876-index-headers.html | 0001437749-26-022876 |
| Document: 0001437749-26-022876-index.html | 0001437749-26-022876 |
| Document: 0001437749-26-022876.txt | 0001437749-26-022876 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 28, 2026 9w ago | 8-K | $0.4800 $0.5000 | ▲ +4.17% | ▲ +0.79% | $0.4370 (−8.96%) |
Jul 7, 2026 12w ago | 8-K | $0.5500 $0.6000 | ▲ +9.09% | ▲ +5.93% | $0.4370 (−20.55%) |
Jul 6, 2026 12w ago | DEFA14A | $0.6200 $0.5900 | ▼ −4.84% | ▼ −5.69% | $0.4370 (−29.52%) |
Jul 2, 2026 13w ago | DEFA14A | $0.6400 $0.5490 | ▼ −14.22% | ▼ −14.52% | $0.4370 (−31.72%) |
Jul 2, 2026 13w ago | 8-K | $0.6400 $0.5200 | ▼ −18.75% | ▼ −18.34% | $0.4370 (−31.72%) |
Jun 26, 2026 13w ago | DEFA14A | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4370 (−23.33%) |
Jun 26, 2026 13w ago | DEFA14A | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4370 (−23.33%) |
Jun 26, 2026 14w ago | 8-K | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4370 (−23.33%) |
Jun 16, 2026 15w ago | DEFA14A | $0.5600 $0.5300 | ▼ −5.36% | ▼ −6.21% | $0.4370 (−21.96%) |
Jun 8, 2026 16w ago | DEFA14A | $0.5800 $0.5502 | ▼ −5.14% | ▼ −6.53% | $0.4370 (−24.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access